Comparative Pharmacology
Head-to-head clinical analysis: ARYNTA versus DURAGESIC 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYNTA versus DURAGESIC 75.
ARYNTA vs DURAGESIC-75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYNTA (pembrolizumab) is a humanized monoclonal antibody that binds to the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2, thereby restoring anti-tumor immune responses.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
400 mg orally once daily
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in healthy adults, prolonged to 6-12 hours in moderate to severe renal impairment (CrCl <30 mL/min).
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Primarily renal elimination (70-80% unchanged), with 10-15% fecal excretion via biliary secretion.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic